With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

The dollar fell against a basket of currencies after reaching a one-month high Tuesday. Investors await the Federal Reserve's policy decision while focus is also on U.S. second-quarter economic growth ...

BAE Systems also came under pressure, falling 24p to 1797p despite its upgrade to 2025 guidance. GSK also surrendered initial ...

(Alliance News) - GSK predicted an annual outturn at the top end of guidance, BAE Systems maintained its outlook, while Aston Martin softened its profit forecast. Here is what you need to know before ...

The Federal Reserve is expected to leave interest rates unchanged at its policy meeting later on Wednesday, though it could ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

While value has outperformed growth in Europe over the past five years, Europe now represents less than half of equity market capitalization outside the US. Rather, value stocks in emerging markets ...

Pharma giant Glaxosmithkline, which has major operations in Upper Providence and West Point, is partnering with China-based ...

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 ...

Asian equities were mostly higher overnight as Vietnam and Indonesia outperformed while Japan and India underperformed. Hong ...

Britain's GSK and China's Jiangsu Hengrui Pharmaceuticals have agreed on a $500 million deal to develop up to a dozen new ...

The deal, which focuses first on a COPD drug GSK believes holds “best-in-class” potential, could involve a dozen medicines ...